STOCKHOLM, Jan. 28, 2025 /PRNewswire/ -- EQT is pleased to announce that EQT Life Sciences has led a USD 75 million Series B funding round in Atalanta Therapeutics ("Atalanta" or "the Company").

A recent study published in Cell reveals that the repeated DNA sequence that leads to Huntington’s disease (HD) expands ...

People genetically susceptible to Huntington's disease often see their movement, mood, and cognition decline slowly over time.

Researchers have made a major breakthrough in our understanding of Huntington's disease. This genetic disorder has long been ...

Scientists are unraveling the mystery of what triggers Huntington's disease, a devastating and fatal hereditary disorder that ...

Subtle changes in the brain, detectable through advanced imaging, blood and spinal fluid analysis, happen approximately twenty years before a clinical motor diagnosis in people with Huntington's ...

CAMBRIDGE, Massachusetts ‒ For decades it's been one of the defining mysteries of Huntington's disease. Why does the terrible ...

Huntington's disease is a hereditary neurodegenerative disorder caused by an autosomal dominant mutation. The hallmark symptom of Huntington's disease is the presence of progressive chorea ...

Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating and fatal hereditary disorder that strikes in the prime of life, causing nerve cells in parts of the ...

Scientists are unraveling the mystery of what triggers Huntington’s disease, a devastating and fatal hereditary disorder that strikes in the prime of life, causing nerve cells in parts of the ...